SRT6 is a CD44 inhibitor. SRT6 exerts antiproliferative activity in CD44+ breast cancer and lung cancer cells. SRT6 inhibits CD44-associated SRC kinase, as well as EGFR, ERBB2, ERBB4, MAP3K10 and MAPKAPK2. SRT6 can be used for the research of breast cancer and lung cancer[1].
Molecular Weight:
514.55
Formula:
C25H26N2O8S
Target:
CD44,EGFR,MAPKAPK2 (MK2),Src
Application Notes:
MCE Product type: Reference compound
* VAT and and shipping costs not included. Errors and price changes excepted
